Canadian policymakers must act to bolster the country’s local production base for off-patent drugs, after learning “difficult lessons” from the coronavirus pandemic, according to Jim Keon, president of the Canadian Generic Pharmaceutical Association.
Canada Must Learn ‘Difficult Lessons’ From COVID-19
CGPA’s Keon Urges Strengthening Domestic Industry Amid Global Supply Chain
Canadian policymakers must learn “difficult lessons” from the coronavirus pandemic and support measures to bolster domestic production and secure the country’s position as part of the global supply chain, according to CGPA president Jim Keon.

More from Policy & Regulation
More from Generics Bulletin
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.